Consensus Group

Prof. Ali Asghar A Lanewala Dr. Irshad Ali Bajeer

Prof. Seema Hashmi Dr. Afshan Ehsan
Prof. Khemchand Moorani Dr. Madiha Aziz
Dr. Veena Tresa Dr. Sadaf Asim
Dr. Sabeeta Khatri Dr. Bilquis Abro

Compiled by
Dr. Irshad Ali Bajeer Prof. Ali Asghar Anwar Lanewala

Endorsed by
Pakistan Pediatric Association- Nephrology Group

Depatement of Paediatric Nephrology

Sindh Institute of Urology and Transplantation

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 1

Introduction Since these results have not been incorporated in most

of the Textbooks of Pediatrics, we believe that this
Childhood Nephrotic Syndrome is one of the most
document will help all the practicing physicians to review
common kidney disease encountered in children.
the literature and adapt to the current recommendations.
Pakistan is the 6th most populous country of the world
with more than 200 million population out of which 31% We have compiled these guidelines with best intentions
are between the ages of 0 - 14.1 for our children and have tried to incorporate all the
common varieties and complications associated with
The exact etiology of this disease is still unknown;
this disease. It is by no means complete and final. All
however; in children; vast majority gets better with
physicians are advised to use their personal judgment
immune suppression. The recommended protocol of
in individual cases and we beg to communicate with us
treatment for different varieties of Nephrotic Syndrome
if there are any differences in opinion or experience.
has been revised based on current evidence.
In Pakistan, due to very few qualified pediatric
nephrologists, these children are usually treated by family Nephrotic Syndrome (NS)
physicians, pediatricians and adult nephrologists. Each Diagnosis of NS:
treating physician follows different protocols and in
Nephrotic Syndrome is characterized by:
many cases children are either inadequately treated or
have received over treatment. This results in increased a. Progressively increasing edema
morbidity and in many cases long term complications. b. Hypoalbuminemia (< 2.5 mg /dl)
The Pakistan Pediatric Association Nephrology Group c. Proteinuria (> 40mg/m2/hr or Pr: Cr > 2)
has felt the need to standardize the protocols for d. Hypercholesterolemia (> 200 mg /dl)
treatment of this disorder based on current evidence all
In exceptional cases with heavy proteinuria, the quantity
over the country so that this potentially treatable
of proteinuria measured at the time of presentation could
condition can be addressed uniformly.
be lower, however if the other 3 features are present the
A consensus group was formed between the Pediatric diagnosis can be made.
Nephrology Departments of the Sindh Institute of
In almost one third of cases there is microscopic hematuria
Urology and Transplantation (SIUT) and the National
and hypertension at the time of diagnosis. In such cases
Institute of Child Health (NICH) who met regularly and
history of progressively increasing edema and high serum
discussed all the current practices and personal
cholesterol is most helpful to exclude the diagnosis of
experiences in light of recent evidence.
Acute Nephritic Syndrome.2
A document was compiled and circulated electronically
Classification based on the age of onset:
amongst all the members of our group and objections
to these protocols were invited. After reaching consensus Congenital NS (< 3months)
amongst the group these guidelines were compiled in Infantile NS (3months to 1 year)
a publication form and circulated across the country Childhood NS (1 to 12 years)
using the platform of Pakistan Pediatric Association and
the Pakistan Society of Nephrology. Adolescent NS (> 12 years)

It must be emphasized that these guidelines are based Classification on the basis of response to steroids:
on current evidence based researches which are still Based on the response to treatment with steroids, NS can
evolving. The most notable difference in last 5 years is be classified into:
the duration of steroids that should be given for the first Steroid Sensitive Nephrotic Syndrome (SSNS)
episode and relapses. It has been noted that there is no
Steroid Resistant Nephrotic Syndrome (SRNS)
statistically significant difference in the number of
relapses between cohorts who receive short duration of SSNS can be further classified based on the relapse pattern
treatment (2 to 3 months) compared to prolonged into:
duration (6 months). Steroid Dependent Nephrotic Syndrome (SDNS)

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 2
Frequently Relapsing Nephrotic Syndrome (FRNS) Use of Antacids with Steroids
and It is customary to prescribe antacids with steroids.
Infrequently Relapsing Nephrotic Syndrome (iFRNS) Aluminum containing antacids are known to decrease
the absorption of steroids and H2 receptor blockers like
Definitions:
ranitidine should be prescribed at a dose of 2 to 4 mg/kg
SSNS: Complete remission of edema and proteinuria /day to a maximum of 150 mg/day while proton pump
within 6 weeks of full dose (2mg/kg/day). inhibitors can be prescribed at 1mg/kg/day as once daily
o SDNS: Two consecutive relapses on tapering dose. Some authorities recommend using antacids only
steroids or within 2 weeks of stopping steroids on as needed basis. In these consensus guidelines we
have left the decision on the discretion of treating
o FRNS: Two relapses in initial 6 months or 4 relapses
physician. It must also be kept in mind that ranitidine may
in any 12 months
give false positive result for protein on "Multistic". 5
o iFRNS: Less than 4 relapses in a year.

Dose of Steroids
SRNS: Persistent proteinuria and edema after 4 weeks Dose of steroids should be calculated as mg/kg.
of treatment with daily dose of 2mg/kg/day. In cases Calculations based on body surface area have been found
where there is partial response to edema and decrease to give a higher cumulative dose of steroids and no
in the quantity of proteinuria from the baseline after a dditional benefit in terms of relapse rate. 6
4 weeks, the treatment can be prolonged up to 6
It is recommended to give the dose as a once daily dose
weeks.3
as compared to divided dose because it results in lesser
adrenal suppression and lesser side effects of steroids.7

Course of Treatment
We recommend treatment of first episode of NS with
prednisolone for 12 weeks. The dosage should be
2mg/kg/day taken once daily for 4 weeks followed by 1.5
mg/kg every other day (EOD) for 8 weeks. At the end of
12 weeks steroids should be stopped without tapering.
A total of 3 follow up visits are advised at 2, 4 and 12
weeks.
Figure-1: Classification of Nephrotic Syndrome.
First Follow up: The median time to respond to full dose
of steroids is 11 days (10 - 15 days). 8 We therefore
Treatment of first Episode recommend that the first follow up should be done after
Children presenting with nephrotic syndrome for the first 2 weeks to ensure that the child is in remission and edema
time after 3 months of age to 12 years of age should be has resolved. Only a urine dipstick done in the office is
treated initially with steroids. sufficient to document absence of proteinuria. Trace
Choice of Steroids proteinuria on dipstick (<500 mg/ 24 hours) should be
Prednisolone has remained a reference drug. In Pakistan considered as remission.
it is available as 5 mg tablets and 15mg/5ml suspension. This is in contrast to most other guidelines where
We recommend use of plain (non-enteric coated) tablets documentation of negative proteinuria for 3 consecutive
as it is cheaper and has better absorption. Moreover the days is recommended. In our setup provision of dipsticks
risk of gastro-intestinal bleeding due to steroids in to the parents is usually not possible. Other methods to
ambulatory patients is 0.13% therefore; use of enteric check proteinuria; like boiling urine; is cumbersome and
coated prednisolone may not confer any additional a source of anxiety for the parents and the child. We
benefit.4 therefore recommend checking urine dipstic only once
at 2 weeks to document remission.

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 3
Re-enforcement of counseling about need for compliance, our group, in these guidelines we have suggested use of
anticipated side effects and balanced diet should be done lower cumulative dose with 12 weeks therapy.
on this visit. Even if proteinuria and edema persists after
2 weeks next follow up is advised again after 2 weeks.
Second Follow up: On second follow up at 4 weeks from
start of steroids, if the proteinuria and edema persists
child should be labeled as primary SRNS and further
treatment is advised as per protocol mentioned on page
16.
If the child is in remission then the dose should be reduced
to 1.5mg/kg every other day (EOD) for next 8 weeks
without tapering to complete a total duration of 12 weeks.
In rare cases of late responders, when proteinuria and
edema has decreased but not completely resolved after
4 weeks then trial of full dose for 2 more weeks has been Figure-2: Algorithm of treatment for first episode of Nephrotic Syndrome.
seen to induce remission. In such cases if there is 1. Proteinuria on dipstic: Negative or trace.
proteinuria more than trace even after 6 weeks, they
2. In rare cases if edema and proteinuria has decreased
should be then treated as SRNS.
over 4 weeks of treatment, a trial of full dose for 2
In cases when a delayed response is seen after 6 weeks, more weeks can result in remission.
the dose should be decreased to 1.5mg/kg EOD for
another 6 weeks and then steroids are stopped.

Third Follow up:

Last follow up should be done at 12 weeks and if there is
remission, steroid treatment should be stopped and
parents should be advised to return if there is relapse. It
is suggested to document sustained remission with urine
dipstick at 3 months, 6 months and then annually.

Justifications for the recommended duration:

The optimal duration of treatment for the first episode of
NS is still being debated. Multiple evidence based
guidelines and meta-analysis had shown a superior
outcome with prolonged duration of treatment upto 6
months.9-11 Recently conducted well designed trials have
proven that the number of relapses with shorter duration
of steroids compared to longer duration are not statistically
significant.12-15 However, for shorter duration there is still
*EOD = Every Other Day
no comparative recent trial between 8 weeks versus 12
weeks. APN trials conducted in 1980s have demonstrated
Relapse with Upper respiratory infection
a superior outcome with 12 weeks duration when
Children suffering from SSNS are known to have multiple
compared to standard 8 weeks therapy.16 There are other
relapses. A relapse is confirmed when the child has
trials that have compared cumulative dosages and have
proteinuria and edema. Most of these relapses are
proven that lower cumulative dose has less long term
associated with a preceding viral infection. 17-20
side effects and equal relapse rate. After discussion among
If the child is already receiving alternate day treatment

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 4
with steroids and develops URI with relapse of proteinuria
then the same dose is increased to daily dosage for one
week and if remission is achieved the dose should be
brought back to the baseline. This one week therapy is
additional to the total recommended duration of
treatment for children who were already receiving
treatment.
If the child is already off medications, prednisolone
0.5mg/kg/day for one week is recommended. At the end
of one week if proteinuria has remitted then all
medications should be stopped.In cases where the
proteinuria does not remit after one week of daily
treatment, they should be treated as relapse.
Figure-3: Algorithm of treatment of Relapse of Nephrotic Syndrome.
Treatment of Relapse
Children who develop proteinuria and edema in absence
of a viral infection or those who do not respond to one
week treatment of low dose daily steroids should be
started on full dose Prednisolone (2mg/kg/day) once daily,.
Our group recommends that for relapse the first follow
up should be done at 2 weeks of starting treatment. This
is in contrast to recommendations by many authorities
to decrease dose once proteinuria has settled for 3
consecutive days. We recommend rechecking proteinuria
after 2 weeks only on one occasion and decrease the dose
if there is negative or trace proteinuria. This
recommendation is based on the fact that the median
time to respond is around 2 weeks. To check for negative
proteinuria on 3 consecutive days is a huge logistic burden
for most public health setups and may also cause
unnecessary parental anxiety.
of kidney lesions in this age group is different from that
On first follow up for relapse after 2 weeks of full dose, if
of children with higher incidence of membranous
the child is in remission the dose should be decreased to
nephropathy.22 More children in adolescent age groups
1.5 mg/kg/ EOD for another 6 weeks and then the
are noted to have SRNS. The protocol for the treatment
treatment is stopped.21
of Adolescent NS remains same as that of childhood except
In case of persistent proteinuria and edema for 4 weeks that we recommend performing a kidney biopsy before
the child should be labeled as "Secondary SRNS" and starting treatment along with serologic markers for
further treatment should be done as described on page Hepatitis B and C, anti- nuclear anti body (ANA), anti-
number 16. double stranded DNA antibody (anti-dsDNA) and serum
The duration of treatment for relapse is also not clearly complements (C3 and C4).23
defined and varies in different protocols. This duration of
8 weeks was decided by our group based on our personal Treatment of SDNS
experience and observations. Children who have had 2 consecutive relapse while
tapering steroids or within 2 weeks of stopping treatment
Treatment of Adolescent NS with steroids should be treated with a steroid sparing
First episode of NS after 12 years of age is labeled as agent.
Adolescent NS. It has been shown that the morphology

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 5
The first choice of alternate medication in SDNS should Table-1: Example calculation of dose of Cyclophosphamide.
be Cyclophosphamide (CyP) as it has shortest duration of Example calculation: Weight 10 kg
treatment with best results as compared to all other Cumulative dose: 168mg /kg = 1680 mg
agents.24,25 Daily Dose (2-3mg / kg): 25mg
Number of days = cumulative dose/daily dose = 1680/25 = 67 days or
The recommended cumulative dose is 168mg/kg and the 9 weeks and 4 days
daily dose should be between 2 to 3 mg/kg. Sample * Follow-up with complete blood count every 2 weeks to look for leucopenia
calculation is shown in Table. Based on these calculations ** Withhold cyclophosphamide if leukocyte count is < 4000. Restart treatment
the total duration of treatment with CyP should be after 1 to 2 weeks once leukocyte count is more than 4000 and adjust the lost
days in total duration.
between 56 to 84 days (8 -12 weeks).
Before starting treatment with CyP, complete remission
Treatment of FRNS
Children who have frequent relapses (2 relapses in initial
should be achieved by giving 2 weeks of full dose. It
6 months or 4 relapses in any 12 months) are at risk of
should be remembered that CyP is not so effective in
receiving high dose of steroids over a long period of time.
SRNS so only children who have achieved remission with
There is strong evidence that these children benefit from
steroids should be offered this therapy. Bone marrow
a course of levamisole.24-26
suppression is the most common side effect so total
leukocyte count (TLC) should be monitored every 2 weeks Levamisole not only has antihelminthic activity but also
for the duration of treatment. If the TLC is less than 4000, works as an immunomodulator. It is marketed in Pakistan
CyP should be held for 1 to 2 weeks till TLC improves. It as Ketress in 40 mg tablets and 40mg/5ml suspension.
should be then restarted with same dose to complete the The recommended dose is 2-2.5mg /kg day as a single
cumulative dose. daily dose given on alternate days. Although there are
studies that have shown a better result of Levamisole with
Prednisolone 1.5 mg /kg/EOD should be given for the first
daily dosages, however after discussion among our group
2 weeks and then reduced by 0.5mg/kg/EOD every 2
the consensus based on personal experiences, we
weeks to reach a minimum dose of 0.25mg/kg/EOD till
recommend Levamisole to be given on alternate days.
the treatment is complete. All the medications can be
stopped at once when the planned duration is complete. It should be started only after complete remission has
Children who relapse after completing the course of been achieved with full dose of steroids. At the beginning
Cyclophosphamide should have a kidney biopsy and 1.5mg/kg/EOD prednisolone should be given for initial 4
treatment with Cyclosporine should be offered. The weeks. It should be then tapered by 0.5mg/kg every 2
protocol for Cyclosporine treatment is described under weeks to reach a dose of 0.25mg/kg/EOD over next 8
the section of SRNS. weeks. Steroids can be stopped after one year of treatment.
Although Levamisole has a good safety profile but rarely
neutropenia and ANCA associated vasculitis has been
reported in very few cases. We recommend monthly follow
ups for first 3 months with a Complete Blood Count and
urine dipstick and if the child is tolerating the treatment
well then they can be followed every 3 months till one
year of treatment is completed.
In case if there is a relapse while taking levamisole and
low dose steroid then it should be treated with full dose
of steroids for 2 weeks followed by 1.5mg/kg/EOD for 6
weeks. Steroids should then be brought to the same dose
as it was before the relapse. Children who relapse during
the second year with no steroids should be treated as per
relapse protocol with 2mg/kg/day for 2 weeks and then
1.5mg/kg/EOD for 6 weeks and then stop steroids.
Children who have had 2 relapses while on levamisole
Figure-4: Treatment of Steroid Dependent Nephrotic Syndrome. within a period of 6 months, then levamisole should be

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 6
stopped. These children should then be treated with variants, Focal segmental glomerulosclerosis and IgM
Cyclophospha mide as per pro tocol of SD NS. nephropathy then Calcineurin inhibitors like Cyclosporine
If no relapses are seen with Levamisole for 2 years and at (CyA) or Tacrolimus ( Tac) should be initiated.
least one year without steroids, it can be discontinued. CyA should be started at a dose of 5mg/kg/day in two
equal divided doses along with 1mg/kg/EOD dose of
steroids. It is available in capsules of 25mg, 50mg and
100mg and in liquid formulation containing 100mg/ml.
The first follow up is recommended after 6 weeks of
starting CyA and if complete remission is achieved then
steroids can be tapered by 0.25 mg/kg/EOD every 2 weeks
till it is stopped over 8 weeks.29
Children who still have proteinuria after 6 weeks should
continue the same dose of CyA and steroids for another
6 weeks. If no response is seen after 3 months of therapy,
CyA trough levels should be checked where available and
dose should be adjusted to achieve a trough level of 120
- 150 ng/ml.
Those who respond to CyA with sustained remission after
6 months should receive a tapering dose with
0.5mg/kg/day lower dose every 2 months till a minimum
dose of 1mg/kg/day is reached. Once they maintain
remission on minimum dose for 6 months and have
completed 2 years of total therapy then treatment can be
stopped.
Patients who relapse on tapering dose of CyA should be
Figure-5: Algorithm of treatment for FRNS. brought back to the effective dose with concomitant
steroids at 1 mg/kg/EOD. Steroids can again be tapered
Steroid Resistant Nephrotic Syndrome once remission is achieved.
Children who do not go into remission after 4 weeks of
full dose steroids therapy or those who have partial One commonly used alternate treatment in patients with
response after 6 weeks should be treated as SRNS. These preserved GFR who develop cosmetic side effects due to
patients can have a primary steroid resistance or may CyA is Tacrolimus. In Pakistan it is available in Capsule of
have been sensitive to steroids in the past but develop 0.5mg, 1mg and 5mg. Some pharmacist can constitute a
resistance with subsequent relapses (Secondary SRNS). suspension of required strength if required for younger
SRNS carries the worst long term prognosis in terms of children. It is started at a dose of 0.1 to 0.15mg/kg/day in
renal survival among all other categories of childhood two equally divided doses along with Prednisolone
NS. 1mg/kg/EOD.

They should have a baseline work up to rule out any Due to the higher cost of Tacrolimus, some centers use it
secondary etiology like hepatitis B and C and also only for patients who do not respond to CyA with
screening with serum complement levels to rule out an adequate levels after 6 months. In other centers
underlying nephritic etiology. Mycophenolate Mofetil (MMF) is used at a dose of
500mg/m2 .
Kidney biopsy should be performed as soon as the
diagnosis is established and other alternate treatment is If a positive response is seen with Tacrolimus or MMF
started. within 3 months, steroids can be tapered off followed by
slow taper of Tacrolimus to achieve sustained remission
If the eGFR is more than 90ml/min/1.73m 2 and
with minimum dose for 6 months. Tacrolimus like CyA can
histopathology shows Minimal change disease or its

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 7
then be stoppedafter 2 years of treatment. In cases of no
response, Tacrolimus trough levels should be checked
and dosage should be adjusted to achieve trough levels
of 6 to ng/ml. F/U 6 weeks with Cr , albumin and urine DR

Patients whose eGFR decrease below 60ml/min/1.73m2

should be evaluated thoroughly for any acute illness and
if the renal functions recover to the baseline CyA can be F/U 6 weeks with Cr , albumin and urine DR
restarted with close monitoring.
Patients with no response after 6 months of therapy with
CNI or those who develop renal failure despite adequate
trough levels should be treated with antiproteinuric drugs F/U 8 weeks with Cr , albumin and urine DR
like Angiotensin Converting Enzyme Inhibitors (ACEI) or
Angiotensin Receptor Blocker (ARB), diuretics and statins.
There are successful reports with the use of Rituximab in
such cases. However, since there are no set international
*Effective dose: Dose of cyclosporine on which patient achieved remission
guidelines for the treatment, it should be tailored
according to the availability of resources and expertise of Figure-7: Algorithm of treatment for Relapse on cyclosporine.
the treating center.

F/U every 3 months with Cr , albumin and urine DR

Figure-6: Algorithm o treatment for SRNS. Figure-8: Algorithm for treatment of SRNS with Tacrolimus.

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 8
in adults in developed countries.33 Local data on this
treatment is scant.
For all other children with MN it is recommended that the
urinary protein losses should be quantified using either
24 hours collection or spot urinary protein creatinine ratio
as a baseline.
The mainstay of treatment is ACEI or ARB for initial 6
months. Diuretics can be used judiciously in children with
moderate to severe edema. After 6 months of therapy
urinary protein should be quantified again and if high
grade proteinuria > 4 gm/day persist then consider
immunosuppression with Cyclophosphamide, CNI or
Rituximab.34
Since the availability and experience with different
immune suppression varies among physicians the choice
is left at the discretion of the treating physician.

Figure-9: Algorithm of treatment for Relapse on Tacrolimus. Mesangiocapillary Glomerulonephritis /

Membranoproliferative Glomerulonephritis
(MCGN/MPGN)
Role of ACEI / ARBs Fortunately, the incidence of idiopathic MCGN/MPGN is
Angiotensin Converting Enzyme Inhibitors (ACEI) and low. Children with these lesions may present as either
Angiotensin Receptor Blockers (ARB) are known to Nephrotic Syndrome or with acute deterioration of renal
decrease the filtration pressure in the glomeruli and in functions.35
turn reduce the proteinuria. This anti-proteinuric effect . In cases of MPGN/MCGN when the clinical presentation
of these medications can be used to treat nephrotic is of rapidly progressive glomerulonephritis (RPGN), the
syndrome. Since all Steroid Sensitive varieties respond treatment protocol includes pulse treatment with high
well to steroids therefore, the use of ACEI and ARBs is doses of steroids however, with NS, the evidence to
mostly prescribed for SRNS.30 suggest the benefit of corticosteroids and other
Due to the reduction in filtration pressure the serum immunosuppressive agents is of low quality. 3 6
creatinine may rise reversibly and up to 30% from baseline It is generally treated with Angiotensin converting enzyme
is usually acceptable. Moreover chronic use is associated inhibitors (ACEI) and/or Angiotensin receptor blockers
with chronic cough, anemia hyperkalemia and (ARB) as mainstay of treatment. Other general measures
hypotension, so judicious use with close monitoring is in the treatment of Nephrotic Syndrome like control of
recommended. edema, hypertension, nutrition and vaccination should
be advised as detailed on page number __.
Idiopathic Membranous Nephropathy
Membranous Nephropathy (MN) in children below 12 Congenital Nephrotic Syndrome
years of age is relatively uncommon and was seen in 8% Nephrotic syndrome appearing within 3 months of birth
of children who had undergone kidney biopsy for is labeled as congenital NS. In majority of these cases
Nephrotic Syndrome at a single center in Pakistan.31 It is there is an evidence of genetic mutations and in some
more common in adolescent age group.32 cases it may be a part of a syndrome with other associated
Once all secondary etiologies are ruled out, Anti congenital abnormalities.37 .(33) Please Table _ for these
phospholipase A2 receptor (APLA2) antibody, should be associations.
checked where available. APLA2 antibodies if positive can
be treated with Rituximab as good response is reported

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 9
Table-1: Common associated genetic abnormalities of Congenital Nephrotic Syndrome. Nutrition in Nephrotic Syndrome:
Role of diet and restriction of certain food
groups is a very important aspect of
management of Nephrotic Syndrome.
Multiple food products are considered by
parents to be harmful and responsible for
the disease or its relapse. These
misconceptions and myths are variable
in different cultures a nd ethnic
backgrounds.
It has been observed in our practice in
Pakistani population that some parents
consider rice, salt, oil, beef, spices and
-1AD = Autosomal Dominant, FSGS = Focal Segmental Sclerosis, DMS = Diffuse other food products to be so harmful that the food for a
Mesangial Sclerosis, MCD = Minimal Change Disease, CMV= Cytomegalovirus child with Nephrotic Syndrome is cooked separately with
no salt or oil.
Approach to a child with CNS There is no scientific evidence for the beneficial role of
If the Nephrotic Syndrome is diagnosed within 3 months
these restrictions. Only during the acute phase it is
of life the baseline investigations should include antibody
recommended to restrict fluids according to the urine
profile to rule out congenital TORCH (Toxoplasmosis,
output and avoid added salt till edema is present.
Rubella, Cytomegalovirus, Herpes Simplex and Syphilis)
O therwise advise hygienic and balanced diet.
infections and HIV exposure in utero.
Due to heavy protein losses these children are at a very Treat ment of Edema in Nephrotic Syndrome:
high risk to acquire thyroglobulin deficiency which may The most worrying aspect of nephrotic syndrome for
have serious neurologic consequences during infancy. parents is edema. In most cases with mild to moderate
We recommend to start thyroxine replacement while edema, only fluid and added salt restriction is best to
thyroid profile is awaited and tailor the dose according avoid electrolyte and volume related issues. Diuretics are
to TSH levels. In children with normal TSH levels but heavy indicated only if significant edema is present which is
proteinuria we usually continue low dose thyroxine with causing discomfort in walking and lying down. Oral
close monitoring of thyroid profile. Furosemide at 1-3mg/kg daily for 3 to 5 days is usually
To reduce proteinuria it is recommended to treat with advised. Other class of diuretics like thiazide and potassium
Enalapril (0.2 to 0.6 mg/kg/day). Diuretics can be used for sparing drugs can be added if there is no response to loop
severe edema either as IV infusion or as daily oral dose, diuretics. In diuretic resistant edema intravenous albumin
however it should be borne in mind that chronic use of (1gm/kg) is advised along with judicious dose of
loop diuretics may result in electrolyte abnormalities and furosemide (2-3mg/kg). Since intravenous albumin has
diuretic resistance. short half life and it's costly so it should be used judiciously.
It is better to avoid albumin infusion in compromised
This entity carries poor prognosis specially in developing
renal function due to risk of pulmonary edema.38 In such
countries where renal replacement therapy for small
children is not widely available. In developed countries cases of renal failure and severe anasarca with respiratory
distress, acute peritoneal dialysis or simply drainage of
early initiation of peritoneal dialysis and nutritional build
ascitic fluid has been done to relieve the respiratory
up through PEG tube followed by cadeveric kidney
transplantation has been used successfully to treat these distress.
children.31
It is imperitive to counsel the parents regarding the The dosages of diuretics are given in table 2
prognosis and risk of recurrence in future pregnancies.

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 10
Table-2: Dosages of different diuretics. in most cases does not provide any high yield diagnostic
information. First dose of antibiotics (Ceftriaxone
70mg/kg/day) should be given immediately. Total duration
of antibiotics is tailored according to clinical response, blood
culture and sensitivity report. A total of 5 to 7 days of
antibiotics is usually enough to treat mild to moderate
infection. In cases of severe infection with evidence of septic
shock or a beta lactam resistant pneumococcus addition
of Vancomycin may be considered. Due to the increasing
prevalence of multidrug resistant bacteria in Pakistan,
judicious use of broad spectrum antibiotics must be ensured.

Cellulitis
Children with nephrotic syndrome are at risk of soft tissue
infections. During acute disease they lose globulins and
other regulatory proteins of the immune system. Moreover,
they are receiving high dosages of immune suppressant
medications, which make them prone to severe infections.
Simple and localized cellulitis in these children may rapidly
progress into necrotizing fasciitis. Prompt evaluation and
treatment of soft tissue infections in these children is
strongly recommended.
A thorough clinical examination is essential to document
warmth, site, extent, color, tenderness, collection and bullae
formation. Complete blood count, C- reactive protein, blood
Figure-10: Algorithm of treatment for Relapse on Tacrolimus. culture and tissue/pus culture (If obtained after incision
and drainage of collection or debridement) should be sent
and empirical broad spectrum antibiotics are started. Choice
Infectious complications of nephrotic
of definitive antibiotic and duration of therapy depends on
syndrome
clinical response and culture report.
Spontaneous Bacterial Peritonitis (SBP)
Varicella
Fungal infections Varicella infection
Varicella infection (Chicken pox) and Zoster (Shingles) may
Spontaneous Bacterial Peritonitis (SBP) be a serious disease in immune suppressed patients.
SBP affects 1.7 - 3.7 % children with nephrotic syndrome.39 Diagnosis is clinical based on presence of crops of vesicular
Most common organism involved is Streptococcus
lesions in different stages of healing all over the body. Same
Pneumoniae. Other bacteria involved can be Staphylococci,
infection localized to a sensory dermatome is called zoster
Escherichia Coli and Haemophilus Infleunzae. 4 0 and represents reactivation of previous infection.
Usually child presents with fever, vomiting, abdominal pain
In children with nephrotic syndrome due to their
and distension. Clinical examination reveals abdominal
compromised immune status such viral infections can
tenderness and ascites. Required blood workup includes disseminate rapidly. Immunosuppresion should be stopped
complete blood count and blood culture. Diagnostic
or reduced and acyclovir (80mg/kg/day divided every 6
paracentesis should be avoided in these cases because it
hours for 5 days) should be started. Renal functions are
may leak ascitic fluid from the puncture site resulting in monitored and child should be kept adequately hydrated.41
cellulitis and may even lead to peritonitis. The diagnostic
yield of this test is also not superior to blood cultures and In non immune child with accidental exposure to varicella
patient, post exposure prophylaxis with VZIG within 96

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 11
hours is recommended or acyclovir orally (40mg/kg/day Oral / esophageal candidiasis:
divided 4 doses for 7 days) can be given. 4 2 (4) Oral or esophageal candidiasis (Commonly known as oral
thrush) is caused by candida species. In mild to moderate
Fungal infections involvement local application of miconazole, nystatin and
Immunosuppresion in nephrotic syndrome can lead to clotrimazole is enough. If no response is seen or involvement
various fungal infections, most commonly observed are is severe at presentation specially when dysphagia is present
tinea versicular, tinea corporis, oral and esophageal then systemic Fluconazole is recommended. 44 (6)
candidiasis.
Tinea Versicular Vaccination
For children who have missed their scheduled vaccination
It presents as whitish spots and most of the time wrongly
program according to the Extended Program of
labeled as sign of calcium deficiency. It is treated withlocal
Immunization (EPI), catch up immunization is advised.
application of terbinafine, miconazole and clotrimazole.
Non- EPI vaccines like varicella and influenza should be
given as these viral infections may cause relapse and
significant morbidity in non-immunized children with
Nephrotic Syndrome.
All the vaccinations should ideally be carried out during
the remission phase when they are off immune suppression.
Children during the acute phase of illness or while on
immune suppressive medications should not receive live
vaccines like Varicella, measles, mumps, rubella, rotavirus
and oral polio.
Due to the high incidence of communicable diseases in
Pakistan we recommend that Live vaccines should be
deferred until:

Prednisolone dose is less than 1mg/kg/day or total

Figure-11: Algorithm of treatment for Relapse on Tacrolimus. dose is less than 20mg /day for children who weigh
more than 20 kg.
Tinea Corporis:
At least 1 months post cyclophosphamide, CNI and
Most commonly presents with annular patch or plaque,
MMF
raised scaling border and central clearing. Usually treated
with topical miconazole, clotrimazole and terbinafine.43(5)
Alternate Steroids and their equivalent
dosages
In most cases the steroid of choice is plain prednisolone
tablets. Enteric coated forms can be used, however the
bioavailability may decrease and there is additional cost
with no significant benefit. Other steroids like
hydrocortisone, dexamethasone and deflazacort have been
used in small trials with no significant benefit and hence
not recommended.
If a child for any reason cannot swallow medications during
acute illness then a nasogastric or oral tube can be used
to administer Prednisolone. In rare cases Intravenous
formulations can be given with following conversions.

Figure-12: Lesion of Tinea corporis.

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 12
Lancet.1:380-3
16. Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV,
Abeyagunawardena S, Illangasekera YA, Karunadasa UI, et al. Short
courses of daily prednisolone during upper respiratory tract infections
reduce relapse frequency in childhood nephrotic syndrome. Ped
Neph 32(8):1377-82.
17. Abeyagunawardena AS, Trompeter RS (2008) Increasing the dose of
prednisolone during viral infections reduces the risk of relapse in
nephrotic syndrome: a randomized controlled trial. Arc of Dis in Child
93(3):226-8.
18. Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A (2011) Daily
References corticosteroids reduce infection-associated relapses in frequently
1 Andolino TP, Reid-Adam J (2014). Nephrotic syndrome. Ped in Rev relapsing nephrotic syndrome: a randomized controlled trial. CJASN
36(3):117-25. 6(1):63-9.
2. Bagga A. (2008) Management of steroid sensitive nephrotic syndrome: 19. Uwaezuoke SN (2015). Steroid-sensitive nephrotic syndrome in
Revised Guidelines. Ind Ped 45(3): 203-214. children: triggers of relapse and evolving hypotheses on pathogenesis.
Ital J of Ped 41(1):19.
3. Narum S, Westergren T, Klemp M (2014) Corticosteroids and risk of
gastrointestinal bleeding: a systematic review and meta-analysis. 20. Bagga A (2008). Revised guidelines for management of steroid-
BMJ Open 4:e004587. doi:10.1136/bmjopen-2013004587 sensitive nephrotic syndrome. Ind J of Nephrol 18(1):31.
4. Engoran B and Flerlage J (2014), The Harriet Lane Handbook (20th 21. Mubarak M, Kazi JI, Lanewala A, Hashmi S, Akhter F (2012). Pathology
ed), Chapter 29 Page 928, Philadelphia, Pensylvania: Saunders. of idiopathic nephrotic syndrome in children: are the adolescents
different from young children? NDT 27(2):722-6.
5. Raman V, Krishnamurthy S, Harichandrakumar KT (2016) Body weight-
based prednisolone versus body surface area-based prednisolone 22. Pradhan SK, Satpathy SK, Bhat S, Krishnamoorthy A (2018). Single
regimen for induction of remission in children with nephrotic center experience on histopathological spectrum and treatment
syndrome: a randomized, open-label, equivalence clinical trial. Ped profile in adolescent-onset nephrotic syndrome in India. J Ped
Neph 31(4): 595-604. Neph.6(1). DOI: 10.22037/j ped nephrology.v6i1.20566
6. Ekka BK, Bagga A, Srivastava RN (1997) Single-versus divided-dose 23. Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, …. Loirat C
prednisolone therapy for relapses of nephrotic syndrome. Ped Neph (2011). Cyclophosphamide in steroid-dependent nephrotic syndrome.
11(5): 597-599. Ped Nep 26(6):927-32.
7. Brodehl J, Krohn HP (1979) Alternate-day versus intermittent 24. Bajeer IA, Khatri S, Tresa V, Hashmi S, Mubarak M, Lanewala AA (2017).
prednisone in frequently relapsing nephrotic syndrome. Lancet 1:401- Histopathological Spectrum and Short-Term Outcome of Treatment
404. with Cyclophosphamide in Relapsing Steroid-Sensitive Nephrotic
Syndrome. JCPSP 28(6):436-9.
8. Hodson EM, Knight JF, Willis NS, Craig JC (2008) Corticosteroid therapy
in nephrotic syndrome: a meta-analysis of randomised controlled 25. Samuel EMK, Krishnamurthy S, Bhanudeep S, Muske S (2017).
trials. Arch of Dis in Child 83(1):45-51. Levamisole in frequently-relapsing and steroid-dependent nephrotic
syndrome. Ind Ped.54(10):831-4.
9. Hodson EM, Habashy D, Craig JC (2006) Interventions for idiopathic
steroid resistant nephrotic syndrome in children. Cochrane Database 26. Fu L-S, Shien C-Y, Chi C-S (2004). Levamisole in steroid-sensitive
of Systematic Reviews. 2006(2): CD003594. nephrotic syndrome children with frequent relapses and/or steroid
dependency: comparison of daily and every-other-day usage. Neph
10. Hahn D, Hodson EM, Willis NS, Craig JC (2015) Corticosteroid therapy
Clin Pract.;97(4):c137-c41.
for nephrotic syndrome in children. Cochrane Database of Systematic
Reviews Issue 3. Art. No.: CD001533. DOI: 27. Sinha A, Bagga A (2017). Levamisole: Standard or Intensive Therapy?
0.1002/14651858.CD001533.pub5 Ind Ped 54(10):815-6.
11 Ehrich JHH, Brodehl J (1993) Long versus standard prednisone therapy 28. Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP,….
for initial treatment of idiopathic nephrotic syndrome in children. Johnson K (1996). Long-term cyclosporine therapy for pediatric
Eur Jou of Ped 152(4):357-61. nephrotic syndrome: a clinical and histologic analysis. JASN 7(4):543-
9.
12. Teeninga N, Kist-van Holthe JE, van Rijswijk N, de Mos NI, Hop WC,
Wetzels JF, van der Heijden AJ, Nauta J (2013) Extending prednisolone 29. Bagga A, Mudigoudar BD, Hari P, Vasudev V (2004). Enalapril dosage
treatment does not reduce relapses in childhood nephrotic syndrome. in steroid-resistant nephrotic syndrome. Ped Neph 19(1):45-50.
J Am Soc Nephrol; 24(1):149. 30. Mubarak M, Lanewala A, Kazi JI, Akhter F, Sher A, ….. Fayyaz A (2009).
13. Yoshikawa N, Nakanishi K, Sako M, Oba MS, Mori R, Ota E, Ishikura K, Histopathological spectrum of childhood nephrotic syndrome in
Hataya H, Honda M, Ito S, Shima Y, Kaito H, Nozu K, Nakamura H, Pakistan. Clin and Exp Neph 13(6):589.
Igarashi T, Ohashi Y, Iijima K (2015). A multicenter randomized trial 31. Mubarak M, Kazi JI, Lanewala A, Hashmi S, Akhter F (2012). Pathology
indicates initial prednisolone treatment for childhood nephrotic of idiopathic nephrotic syndrome in children: are the adolescents
syndrome for two months is not inferior to six-month treatment. different from young children? NDT 27(2):722-6.
Kidney Int; 87(1):225-32. Epub 2014 Jul 23
32. Ruggenenti, P., Debiec, H., Ruggiero, B., Chianca, A., Pellé, T., Gaspari,
14. Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, Kalaivani M, F., ... Remuzzi, G. (2015). Anti-Phospholipase A2 receptor antibody
Hari P, Bagga A (2015). Extending initial prednisolone treatment in titer predicts post-rituximab outcome of membranous nephropathy.
a randomized control trial from 3 to 6 months did not significantly JASN 26(10), 2545-2558. https://doi.org/10.1681/ASN.2014070640
influence the course of illness in children with steroid-sensitive
nephrotic syndrome. Kidney Int.; 87(1):217-24. Epub 2014 Jul 16 33. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, ….. Filippi
C (2003). Rituximab in idiopathic membranous nephropathy: a one-
15. Nephrologie AFP (1988). Short versus standard prednisone therapy year prospective study. JASN 14(7):1851-7.
for initial treatment of idiopathic nephrotic syndrome in children.

Department of Paediatric Nephrology, SIUT

Consensus guidelines for the treatment of Nephrotic Syndrome in Children 13
34. Khatri S, Bajeer IA, Tresa V, Hashmi S, Mubarak M, Lanewala AA (2017). 39. Uncu, N., Bülbül, M., Y?ld?z, N., Noyan, A., Ko?an, C., Kavukçu, S., ...
Short-term outcome of clinical and histopathologic variants of & Güven, A. G. (2010). Primary peritonitis in children with nephrotic
mesangiocapillary glomerulonephritis in children: A retrospective syndrome: results of a 5-year multicenter study. European journal of
analysis from a tertiary care center. JPMA 68: 1199-1204. pediatrics, 169(1), 73
35. Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, ……. Mariani 40. Wiegering, V., Schick, J., Beer, M., Weissbrich, B., Gattenlöhner, S.,
LH (2012). KDOQI US commentary on the 2012 KDIGO clinical practice Girschick, H. J., ... & Eyrich, M. (2011). Varicella-zoster virus infections
g uideline for glomerulonephritis. A JKD 62(3):403-41. in immunocompromised patients-a single centre 6-years analysis.
36. Jalanko H (2009). Congenital nephrotic syndrome. Pediatric BMC pediatrics, 11(1), 31
Nephrology 24(11): 2121-2128. 41. Goldstein, S. L., Somers, M. J. G., Lande, M. B., Brewer, E. D., & Jabs, K.
37. Pasini, A., Benetti, E., Conti, G., Ghio, L., Lepore, M., Massella, L, ... L. (2000). Acyclovir prophylaxis of varicella in children with renal
Pennesi M. (2017). The Italian Society for Pediatric Nephrology (SINePe) disease receiving steroids. Pediatric Nephrology, 14(4), 305-308
consensus document on the management of nephrotic syndrome 42. Andrews, M. D., & Burns, M. (2008). Common tinea infections in
in children. Ital J Ped 43(1). DOI: 10.1186/s13052-017-0356-x children. American family physician, 77(10)
38. Hingorani, S. R., Weiss, N. S., & Watkins, S. L. (2002). Predictors of 43. Akpan, A., & Morgan, R. (2002). Oral candidiasis. Postgraduate medical
peritonitis in children with nephrotic syndrome. Pediatric nephrology, journal, 78(922), 455-459.
17(8), 678-682

Department of Paediatric Nephrology, SIUT